
NeuroDetect is developing a software platform that utilizes machine learning algorithms to create precision-guided biomarker profiles for patients with neurological disorders. Their mission is to provide medical professionals with objective in vitro tools for diagnosing, assessing severity, and guiding treatment for genetic-based neurological disorders, addressing the current gap where patients often face delays in diagnosis or treatment identification. The NeuroDetect Bioprofiler integrates human induced pluripotent stem cells (IPSCs), microelectrode array (MEA) technology for cellular electrophysiology recording, and genomics data. Machine learning analyzes this data to provide functional diagnoses, disease severity estimates, and therapeutic recommendations. Their research is published in BMC Medical Informatics and Decision Making, focusing on the use of machine learning to predict genetic mutation classes from neuronal network models.

NeuroDetect is developing a software platform that utilizes machine learning algorithms to create precision-guided biomarker profiles for patients with neurological disorders. Their mission is to provide medical professionals with objective in vitro tools for diagnosing, assessing severity, and guiding treatment for genetic-based neurological disorders, addressing the current gap where patients often face delays in diagnosis or treatment identification. The NeuroDetect Bioprofiler integrates human induced pluripotent stem cells (IPSCs), microelectrode array (MEA) technology for cellular electrophysiology recording, and genomics data. Machine learning analyzes this data to provide functional diagnoses, disease severity estimates, and therapeutic recommendations. Their research is published in BMC Medical Informatics and Decision Making, focusing on the use of machine learning to predict genetic mutation classes from neuronal network models.
Product: NeuroDetect Bioprofiler — ML-guided software integrating iPSC neurons, MEA electrophysiology, and genomics to generate diagnostic and therapeutic biomarker profiles
Focus: Genetic-based neurological disorders
Headquarters: Palo Alto, California
Founded: 2015
Known funding: Grant announced Jan 22, 2020
Delays and uncertainty in diagnosing and treating genetic-based neurological disorders; need for objective, functional biomarker profiles.
2015
Biotechnology